About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
Targeting CSF-1R to Manage Inflammation and Fibrosis in GVHD
By
Incyte
By
Incyte
0 views
June 3, 2024
© 2024, Incyte. MAT-HEM-03781 05/24
Comments are disabled for this content.
Featured Video
16:51
Incyte
Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk
Feat.
C. Harrison
Featured Video
16:26
Incyte
Effects of a Treatment Option on Hematocrit Control and Spleen Volum…
Feat.
C. Harrison
Recommended
AUTOPLAY
ON
Related
Newest
21:05
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
Feat.
R. Gale
22:37
Insights from 2023 ASH Annual Meeting
AML and MDS Highlights & Key Takeaways
Feat.
T. Badar
17:51
Indy Hematology Review
Treatment of AML: Managing the Patient When Transplant Is Not an Opt…
Feat.
H. Erba
31:53
Indy Hematology Review
HSCT in 2024: What Every Hematologist Needs to Know
Feat.
R. Childs
24:44
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignan…
Feat.
R. Birhiray
09:51
i3 Health
MRD Testing in Leukemias: When Negativity Is a Positive Thing
Feat.
N. S. Raje
27:49
Insights from 2024 EHA Annual Meeting
AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024
Feat.
T. Badar
16:55
Moffitt Cancer Center
Making Sense of the New Classification Systems for MDS in 2024
Feat.
R. Komrokji
19:10
5th SOHO Italy Annual Conference
SOHO Italy 2023: How I Treat AML at MD Anderson Cancer Center
Feat.
H. Kantarjian
14:58
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Optimal Treatment Strategies for Younger P…
Feat.
C. McMahon
22:30
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Emerging Treatment Options for AML in 2024
Feat.
A. Perl
48:04
Icahn School of Medicine at Mount Sinai
Integrating Targeted Therapies in AML
Feat.
H. Kantarjian
28:02
University of Colorado Division of Hematology
2024 Updates in AML
Feat.
C. McMahon
27:26
SOHO Brazil 2024
Where I Use Azacitidine and Venetoclax in AML: Present and Future
Feat.
J. Lancet
27:28
UChicago Medicine
AML: Current Treatment Landscape and Key Recent Updates
Feat.
A. Patel
14:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Immunotherapies in Acute Leukemias: 2024 Update
Feat.
C. Lai
23:15
Rush University Medical Center
Is Post-HSCT Maintenance the SOC for AML?
Feat.
M. Levis
14:19
Talha Badar
Challenges in the Management of TP53-Mutated AML: Potential Strategi…
09:42
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Post-Transplant Cyclophosphamide-Based Gv…
Feat.
M. Al Malki
12:36
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Myeloid for Measure - New Therapeutics in…
Feat.
A. Patel
06:45
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Relationship Between Hemoglobin and QoL in Transf…
Feat.
E. Oliva
06:26
ecancer
Post-Transplant Cyclophosphamide Based GVHD Prophylaxis in Patients …
Feat.
M. Al Malki,
S. Devine
02:38
ecancer
EHA 2024 Insights: APOLLO Trial Summary - ATRA + ATO vs. Standard AT…
Feat.
U. Platzbecker
08:43
Nandita Khera
Maintaining QoL in Chronic GvHD
15:27
Vanderbilt University Medical Center (VUMC)
Age Limits in Stem Cell Transplants and Cell Therapy
Feat.
R. Jayani
23:51
Vanderbilt University Medical Center (VUMC)
Pre-Transplant Management of High-Risk AML
Feat.
K. Fedorov
11:35
Vanderbilt University Medical Center (VUMC)
Prevention and Management of Post-SCT Relapse in Acute Leukemias
Feat.
A. Jallouk
17:42
Vanderbilt University Medical Center (VUMC)
Managing Relapse After CAR-T Therapy in Lymphoma: Strategies and Con…
Feat.
B. Dholaria
14:32
Vanderbilt University Medical Center (VUMC)
Summary of Recent Updates in MDS
Feat.
S. Ball
27:49
Insights from 2024 EHA Annual Meeting
AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024
Feat.
T. Badar
27:26
SOHO Brazil 2024
Where I Use Azacitidine and Venetoclax in AML: Present and Future
Feat.
J. Lancet
19:21
SOHO Brazil 2024
Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde
Feat.
J. Lancet
17:01
SOHO Brazil 2024
Are We Closer to Conquering HR-MDS?
Feat.
R. Komrokji
21:26
SOHO Brazil 2024
Therapies on the Horizon in LR- and HR-MDS
Feat.
R. Komrokji
19:13
SOHO Brazil 2024
Summary of Recent Updates on LR-MDS Management
Feat.
R. Komrokji
19:52
SOHO Brazil 2024
How Are Targeted Therapies Redefining the Treatment Paradigm in ALL …
Feat.
J. Burger
20:33
SOHO Brazil 2024
The Gold Standard in the Use of FLT3 and IDH Inhibitors in AML
Feat.
J. Lancet
13:58
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Intrathecal Rituximab + Dex for Refractory Sanctu…
Feat.
M. Salamoon
26:00
Jane Liesveld
Oral Azacitidine in AML: Results from QUAZAR-AML-001 Trial
09:15
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Low-Molecular-Weight Heparin and VTE in Newly Dia…
Feat.
M. Lauw